ADORA2A

Across TCGA pan-cancer cohorts, ADORA2A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADORA2A data layer compared with 18 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ADORA2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADORA2A expression acts as an unfavorable survival marker.

KIRP, BRCA, and KICH are the cancer types where ADORA2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.176	0.829	<.001	21	view →
BRCA	OS	Median	II,III,IV	0.719	0.958	<.001	20	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.098	0.323	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADORA2A–KIRP (DFS)

Open the KIRP breakdown →